Morgan Stanley’s Cogentix Medical, Inc. CGNT Stock Holding History

Morgan Stanley’s Portfolio CGNT Stock Details CGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-7,646	Closed	-$29K	–	6923
2018 Q1	$29K	Buy	7,646 +5,646	+282%	+$17.7K	﹤0.01%	6046
2017 Q4	$6K	Hold	2,000	–	–	﹤0.01%	6322
2017 Q3	$5K	Sell	2,000 -8,778	-81%	-$19.2K	﹤0.01%	6307
2017 Q2	$18K	Buy	10,778 +2,483	+30%	+$4.26K	﹤0.01%	6118
2017 Q1	$15K	Buy	8,295 +6,295	+315%	+$12.4K	﹤0.01%	6157
2016 Q4	$4K	Buy	+2,000	New	+$4.08K	﹤0.01%	6318
2016 Q2	–	Sell	-39	Closed	–	–	6795
2016 Q1	$0	Sell	39 -6	-13%	-$7	﹤0.01%	6853
2015 Q4	$0	Buy	+45	New	+$62	﹤0.01%	6920
2015 Q3	–	Sell	-17	Closed	–	–	6834
2015 Q2	$0	Buy	+17	New	+$28	﹤0.01%	6850

Morgan Stanley's CGNT Position: Q2 2018 in Review

Morgan Stanley sold out of Cogentix Medical, Inc. (CGNT) in Q2 2018, closing a stake of 7,646 shares — an estimated $29K sold.

Morgan Stanley first reported a position in CGNT in Q2 2015 and held it in 9 quarters. The position peaked at $29K in Q1 2018. 0 funds tracked by Wall St. Rank hold CGNT as of Q2 2018.

Morgan Stanley reported no remaining Cogentix Medical, Inc. position as of Q2 2018 after selling out during the quarter.
Morgan Stanley sold 7,646 Cogentix Medical, Inc. shares in Q2 2018, an estimated $29K.
Morgan Stanley first reported a position in Cogentix Medical, Inc. in Q2 2015 and held it in 9 quarters.
Morgan Stanley's Cogentix Medical, Inc. position peaked at $29K in Q1 2018.
0 funds tracked by Wall St. Rank held Cogentix Medical, Inc. as of Q2 2018.

Based on Morgan Stanley's 13F filing for Q2 2018, filed 14 Aug 2018.